Summary of Korean Asthma Guideline
- Author:
Chin Kook RHEE
1
;
Ji‑Yong MOON
;
Hyonsoo JOO
;
Ji Ye JUNG
;
Jung-Kyu LEE
;
Kyung Hoon MIN
;
Hyeon-Kyoung KOO
;
Seong Yong LIM
;
Hyoung Kyu YOON
;
Sang Yeub LEE
;
Author Information
- Publication Type:Review
- From:Tuberculosis and Respiratory Diseases 2023;86(3):158-165
- CountryRepublic of Korea
- Language:English
- Abstract: Asthma is a chronic inflammatory airway disease that is characterized by variable airflow obstruction. The Korean Asthma Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases has recently updated the Korean Asthma Guideline. This review summarizes the updated Korean Asthma Guideline. Asthma prevalence is increasing worldwide, and in Korea. Variable airflow obstruction can be confirmed by bronchodilator response or other tests, and should be established prior to the controller medication. A low-dose inhaled corticosteroid-formoterol is used to alleviate symptoms in all treatment step, and it can be used as a controller as well as reliever in steps 3–5. This approach is preferred, because it reduces the risk of severe exacerbations, compared to the use of short-acting β2-agonist as reliever. In severe asthma, phenotype/endotype based on the underlying inflammation should be evaluated. For type 2 severe asthma, the biologics should be considered.
